Advertisement

Mass Spectrometry in Clinical Laboratory: Applications in Therapeutic Drug Monitoring and Toxicology

  • Uttam GargEmail author
  • Yan Victoria Zhang
Part of the Methods in Molecular Biology book series (MIMB, volume 1383)

Abstract

Mass spectrometry (MS) has been used in research and specialized clinical laboratories for decades as a very powerful technology to identify and quantify compounds. In recent years, application of MS in routine clinical laboratories has increased significantly. This is mainly due to the ability of MS to provide very specific identification, high sensitivity, and simultaneous analysis of multiple analytes (>100). The coupling of tandem mass spectrometry with gas chromatography (GC) or liquid chromatography (LC) has enabled the rapid expansion of this technology. While applications of MS are used in many clinical areas, therapeutic drug monitoring, drugs of abuse, and clinical toxicology are still the primary focuses of the field. It is not uncommon to see mass spectrometry being used in routine clinical practices for those applications.

Key words

Clinical laboratory Mass spectrometry Liquid chromatography Gas chromatography Tandem mass spectrometry Drugs Therapeutic drug monitoring Toxicology Time-of-flight Immunoassays 

References

  1. 1.
    Hammett-Stabler CA, Garg U (2010) The evolution of mass spectrometry in the clinical laboratory. Methods Mol Biol 603:1–7CrossRefPubMedGoogle Scholar
  2. 2.
    Strathmann FG, Hoofnagle AN (2011) Current and future applications of mass spectrometry to the clinical laboratory. Am J Clin Pathol 136:609–616CrossRefPubMedGoogle Scholar
  3. 3.
    Maurer HH (2007) Current role of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Anal Bioanal Chem 388:1315–1325CrossRefPubMedGoogle Scholar
  4. 4.
    Garg U, Dasouki M (2006) Expanded newborn screening of inherited metabolic disorders by tandem mass spectrometry: clinical and laboratory aspects. Clin Biochem 39:315–332CrossRefPubMedGoogle Scholar
  5. 5.
    Jones PM, Bennett MJ (2002) The changing face of newborn screening: diagnosis of inborn errors of metabolism by tandem mass spectrometry. Clin Chim Acta 324:121–128CrossRefPubMedGoogle Scholar
  6. 6.
    Pagotto U, Fanelli F, Pasquali R (2013) Insights into tandem mass spectrometry for the laboratory endocrinology. Rev Endocr Metab Disord 14:141CrossRefPubMedGoogle Scholar
  7. 7.
    Vogeser M, Parhofer KG (2007) Liquid chromatography tandem-mass spectrometry (LC-MS/MS)—technique and applications in endocrinology. Exp Clin Endocrinol Diabetes 115:559–570CrossRefPubMedGoogle Scholar
  8. 8.
    Soldin SJ, Soldin OP (2009) Steroid hormone analysis by tandem mass spectrometry. Clin Chem 55:1061–1066PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Jimenez CR, Verheul HM (2014) Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications. Am Soc Clin Oncol Educ Book e504–e510Google Scholar
  10. 10.
    Li Y, Song X, Zhao X, Zou L, Xu G (2014) Serum metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 966:147–153CrossRefPubMedGoogle Scholar
  11. 11.
    Whiteaker JR (2010) The increasing role of mass spectrometry in quantitative clinical proteomics. Clin Chem 56:1373–1374CrossRefPubMedGoogle Scholar
  12. 12.
    Ho YP, Reddy PM (2011) Advances in mass spectrometry for the identification of pathogens. Mass Spectrom Rev 30:1203–1224CrossRefPubMedGoogle Scholar
  13. 13.
    Lagace-Wiens P (2015) Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF/MS)-based identification of pathogens from positive blood culture bottles. Methods Mol Biol 1237:47–55CrossRefPubMedGoogle Scholar
  14. 14.
    Luan J, Yuan J, Li X, Jin S, Yu L, Liao M, Zhang H, Xu C, He Q, Wen B et al (2009) Multiplex detection of 60 hepatitis B virus variants by maldi-tof mass spectrometry. Clin Chem 55:1503–1509CrossRefPubMedGoogle Scholar
  15. 15.
    Ojanpera I, Kolmonen M, Pelander A (2012) Current use of high-resolution mass spectrometry in drug screening relevant to clinical and forensic toxicology and doping control. Anal Bioanal Chem 403:1203–1220CrossRefPubMedGoogle Scholar
  16. 16.
    Clarke W, Rhea JM, Molinaro R (2013) Challenges in implementing clinical liquid chromatography-tandem mass spectrometry methods—the light at the end of the tunnel. J Mass Spectrom 48:755–767CrossRefPubMedGoogle Scholar
  17. 17.
    Roux A, Lison D, Junot C, Heilier JF (2011) Applications of liquid chromatography coupled to mass spectrometry-based metabolomics in clinical chemistry and toxicology: a review. Clin Biochem 44:119–135CrossRefPubMedGoogle Scholar
  18. 18.
    Wu AH, French D (2013) Implementation of liquid chromatography/mass spectrometry into the clinical laboratory. Clin Chim Acta 420:4–10CrossRefPubMedGoogle Scholar
  19. 19.
    Armbruster DA, Overcash DR, Reyes J (2014) Clinical Chemistry Laboratory Automation in the 21st century—Amat Victoria curam (Victory loves careful preparation). Clin Biochem Rev 35:143–153PubMedCentralPubMedGoogle Scholar
  20. 20.
    Vogeser M, Kirchhoff F (2011) Progress in automation of LC-MS in laboratory medicine. Clin Biochem 44:4–13CrossRefPubMedGoogle Scholar
  21. 21.
    Vogeser M, Seger C (2010) Pitfalls associated with the use of liquid chromatography-tandem mass spectrometry in the clinical laboratory. Clin Chem 56:1234–1244CrossRefPubMedGoogle Scholar
  22. 22.
    Carvalho VM (2012) The coming of age of liquid chromatography coupled to tandem mass spectrometry in the endocrinology laboratory. J Chromatogr B Analyt Technol Biomed Life Sci 883–884:50–58CrossRefPubMedGoogle Scholar
  23. 23.
    Himmelsbach M (2012) 10 Years of MS instrumental developments—impact on LC-MS/MS in clinical chemistry. J Chromatogr B Analyt Technol Biomed Life Sci 883–884:3–17CrossRefPubMedGoogle Scholar
  24. 24.
    Kortz L, Dorow J, Ceglarek U (2014) Liquid chromatography-tandem mass spectrometry for the analysis of eicosanoids and related lipids in human biological matrices: a review. J Chromatogr B Analyt Technol Biomed Life Sci 964:1–11CrossRefPubMedGoogle Scholar
  25. 25.
    van den Ouweland JM, Vogeser M, Bacher S (2013) Vitamin D and metabolites measurement by tandem mass spectrometry. Rev Endocr Metab Disord 14:159–184CrossRefPubMedGoogle Scholar
  26. 26.
    Peters FT, Remane D (2012) Aspects of matrix effects in applications of liquid chromatography-mass spectrometry to forensic and clinical toxicology—a review. Anal Bioanal Chem 403:2155–2172CrossRefPubMedGoogle Scholar
  27. 27.
    CLSI (2014). In: Clinical and Laboratory Standards Institute (ed.), CLSI Document C62-A, vol 62-A. CLSI, Wayne, PAGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory MedicineChildren’s Mercy Hospitals and ClinicsKansas CityUSA
  2. 2.Department of Pathology and Laboratory MedicineUniversity of RochesterRochesterUSA

Personalised recommendations